US Patent

US12097183 — Pharmaceutical composition for treating migraine

Formulation · Assigned to Tonix Medicines Inc · Expires 2036-01-29 · 10y remaining

Vulnerability score 38/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a method of treating migraine or cluster headache by administering a subcutaneous composition containing 3 mg of sumatriptan base.

USPTO Abstract

The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.

Drugs covered by this patent

Patent Metadata

Patent number
US12097183
Jurisdiction
US
Classification
Formulation
Expires
2036-01-29
Drug substance claim
No
Drug product claim
Yes
Assignee
Tonix Medicines Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.